Portfolio / Rani Therapeutics
BIOTECHNOLOGY / DRUG DELIVERY
Rani Therapeutics
Develops the RaniPill® ingestible robotic capsule for the oral delivery of biologic drugs, without the need for injections.
● PUBLIC
SVLA INVESTMENT
2016
STAGE
Series C
STATUS
Public
NASDAQ: RANI
FOUNDER
Mir Imran
Founder and inventor of the RaniPill®
THE COMPANY
What Rani Therapeutics does
Rani Therapeutics develops the RaniPill®, an ingestible robotic capsule designed to orally deliver biologic drugs that currently require injection. Its goal is to offer patients a needle-free alternative for treatments that are often painful or difficult to sustain over the long term.
TRACK RECORD
Company and market
Based in San Jose, California, the company was founded by Mir Imran, inventor of the RaniPill®. It went public on NASDAQ (RANI) in July 2021. It holds more than 400 granted or pending patents and has completed three Phase 1 clinical studies. Today it develops programs in areas such as obesity and partners with pharmaceutical companies such as Chugai.
SVLA'S INVESTMENT
Why we invested
SV Links Angels invested in Rani Therapeutics in 2016, in its Series C round. The decision was based on its disruptive medical technology, with global patent protection; on the large market of patients who depend on injectable biologic drugs; and on its solid clinical results.